AKTX 2.24 Akari Therapeutics, Plc
| Range: | 1.078-4.4 | Vol Avg: | 16596 | Last Div: | 0 | Changes: | -0.09 |
| Beta: | 0.94 | Cap: | 0.03B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Mon Jan 06 2014 | Empoloyees: | 6 | ||
| CUSIP: | 00972G108 | CIK: | 0001541157 | ISIN: | US00972G2075 | Country: | GB |
| CEO: | Dr. Samir Rashmikant Patel M.D. | Website: | https://www.akaritx.com | ||||
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow